Examples of Incyte Europe in a sentence
The following table represents the preliminary estimate of total purchase price transferred to effect the Acquisition (in thousands): Upfront payments $ 140,000 Contingent consideration 293,000 ARIAD will be eligible to receive from Incyte Europe tiered royalties of between 32% and 50% on net sales of Iclusig in the Territory and up to $135.0 million in potential future oncology development and regulatory approval milestone payments.
Name Jurisdiction of Organization ------------------------------------ ----------------------------------- Incyte Europe Holdings Limited England and Wales Incyte Europe Limited England and Wales Synteni, Inc.
It must be acknowledged that 2020 has been a difficult year; nevertheless, good progress regarding our cooperation with other international organisations has again been made.
Agenus Royalty Purchase Agreement On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive 33% of the future royalties on six Incyte Europe S.a.r.l. (“Incyte”) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and commercial milestones related to these assets.
On June 1, 2016, Incyte Europe acquired ARIAD Europe for total consideration of approximately $433.0 million, calculated as described below.
At the closing of the Acquisition, Incyte Europe paid a purchase price of $140.0 million, subject to customary working capital adjustments (the “Purchase Price”).
ARIAD will be eligible to receive from Incyte Europe tiered royalties on net sales of Iclusig in the Territory and up to $135.0 million in potential future development and regulatory approval milestone payments.
Under the terms of the Share Purchase Agreement, Incyte Europe is indemnified against any and all losses resulting from deferred refund obligations related to the conclusion of pricing and reimbursement negotiations with the National Health Authority.
On June 1, 2016, pursuant to the Share Purchase Agreement dated as of May 9, 2016, among Incyte, as guarantor, Incyte Europe, as purchaser, ARIAD Pharmaceuticals (Cayman) L.P., as seller, and ARIAD, as guarantor, Incyte Europe completed the previously announced acquisition of all of the outstanding shares of ARIAD Pharmaceuticals (Luxembourg) S.à.x.x., the parent company of ARIAD’s European subsidiaries responsible for the development and commercialization of Iclusig in the Territory.
At the closing of the Acquisition, Incyte Europe paid an upfront payment of $147.5 million, including customary working capital adjustments.